Neutrophils and the kallikrein–kinin system in proteinase‐activated receptor 4‐mediated inflammation in rodents
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We evaluated a potential role for proteinase‐activated receptor 4 (PAR 4) in a rodent paw inflammation model, with a focus on two main features of inflammation: (1) oedema and (2) granulocyte recruitment. A PAR 4 antagonist (Pepducin P4pal‐10; palmitoyl‐SGRRYGHALR‐NH 2) reduced both the oedema and granulocyte recruitment induced by a localized administration of carrageenan in the rat hind paw, pointing to a key role for PAR 4 in this inflammation model. Further, intraplantar injection in the mouse hind paw of a PAR 4 agonist (AYPGKF‐NH 2), but not its standard PAR 4‐inactive peptide control (YAPGKF‐NH 2), caused an inflammatory reaction characterized by oedema (increased paw thickness) and granulocyte recruitment (increased paw myeloperoxidase activity). The PAR 4 agonist‐induced effects were inhibited in mice pretreated with pepducin P4pal10. These PAR 4 agonist‐mediated effects were not affected by pretreatment with inhibitors of either NO production or prostaglandin release (L‐NAME and indomethacin, respectively). However, selective immuno‐depletion of neutrophils significantly reduced PAR 4 agonist‐induced oedema formation. Moreover, AYPGKF‐NH 2‐induced oedema was also reduced by pretreatment with either a kinin B 2 receptor antagonist (icatibant) or a tissue or plasma kallikrein inhibitor (FE999024 and FE999026, respectively), but not with a kinin B 1 receptor antagonist (SSR240612). We conclude: (1) that PAR 4 plays an important role in the inflammatory response as it mediates some of the hallmarks of inflammation and (2) that PAR 4‐mediated oedema is dependent on the recruitment of neutrophils and components of the kallikrein–kinin system. British Journal of Pharmacology (2005) 146, 670–678. doi:10.1038/sj.bjp.0706371
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Essential Role for Neutrophil Recruitment to the Liver in Concanavalin A-Induced Hepatitis
Bonder, C. S., Ajuebor, M. N., Zbytnuik, L. D., Kubes, P., & Swain, M. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.45 · Cited by 192 · cited 1×
“…antibody (rat anti-mouse Ly-6G antibody clone RB6-8C5, 125 mg; a dose that has previously shown to deplete mice from their circulating neutrophils by 95%; (Bonder et al., 2004)), a control antibody (rat IgG2bk control antibody; 125 mg) or the vehicle before the i.pl. administration of AYPGKF-NH2.”
Background
Cited by
Ikoma, A., Steinhoff, M., Ständer, S., Yosipovitch, G., & Schmelz, M. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1950 · Cited by 949
Structure, function and pathophysiology of protease activated receptors
Adams, M. N., Ramachandran, R., Yau, M.-K., Suen, J. Y., Fairlie, D. P., Hollenberg, M. D., & Hooper, J. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.003 · Cited by 370
Self-citationChoi, J. E., & Di Nardo, A. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0675-z · Cited by 331
Protease-Activated Receptors in Cardiovascular Diseases
Leger, A. J., Covic, L., & Kuliopulos, A. (2006) · Circulation · doi:10.1161/circulationaha.105.574830 · Cited by 289
Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity
Shpacovitch, V, Feld, M., Hollenberg, M. D., Luger, T. A., & Steinhoff, M. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0108001 · Cited by 190
“In further studies, it was revealed that local injection of PAR4-AP (AYPGKF-NH2) induced neutrophil recruitment and edema formation in a rodent paw inflammation model [20].”
BackgroundSelf-citationProtease-activated receptors in health and disease
Peach, C. J., Edgington-Mitchell, L. E., Bunnett, N. W., & Schmidt, B. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00044.2021 · Cited by 116
Annaházi, A., Gecse, K., Dabek, M., Ait-Belgnaoui, A., Rosztóczy, A., Róka, R., Molnár, T., Theodorou, V., Wittmann, T., Bueno, L., et al. (2009) · Pain · doi:10.1016/j.pain.2009.04.017 · Cited by 112
Protease‐activated receptor‐4 (PAR4): a role as inhibitor of visceral pain and hypersensitivity
Augé, C., Balz‐hara, D., Steinhoff, M., Vergnolle, N., & Cenac, N. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01310.x · Cited by 99
Self-citationLuminal Cathepsin G and Protease-Activated Receptor 4
Dabek, M., Ferrier, L., Roka, R., Gecse, K., Annahazi, A., Moreau, J., Escourrou, J., Cartier, C., Chaumaz, G., Leveque, M., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080986 · Cited by 73
Slofstra, S. H., Bijlsma, M. F., Groot, A. P., Reitsma, P. H., Lindhout, T., ten Cate, H., & Spek, C. A. (2007) · Blood · doi:10.1182/blood-2007-02-075440 · Cited by 66
Yiu, W. H., Wong, D. W. L., Chan, L. Y. Y., Leung, J. C. K., Chan, K. W., Lan, H. Y., Lai, K. N., & Tang, S. C. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088894 · Cited by 50
“Interestingly, recent studies from a rat paw inflammation model showed that edema induced by PAR-4 agonist was blocked by B2R antagonist [53], and PAR-4-induced sensitization of rat joint primary afferents involved B2R activation [54], suggesting a crosstalk between PAR-4 and B2R, but the mechanism remains unknown and…”
Background
Metadata
- Authors
- Houle, S., Papez, M. D., Ferazzini, M., Hollenberg, M. D., & Vergnolle, N.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-11
- Volume
- 146
- Issue
- 5
- Pages
- 670-678
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2028455206
- Cited by
- 97
- References
- 1
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.